Winkelman William D, Missmer Stacey A, Myers Dale, Ginsburg Elizabeth S
Department of Obstetrics, Gynecology and Reproductive Medicine, University of California San Francisco, 505 Parnassus Ave., M1483, Box 0132, San Francisco, CA, 94143, USA,
J Assist Reprod Genet. 2015 May;32(5):665-75. doi: 10.1007/s10815-015-0456-8. Epub 2015 Mar 11.
To study the perspectives of the United States population towards the use of preimplantation genetic diagnosis (PGD) in various clinical scenarios.
Online cross-sectional population based questionnaire of a nationally representative sample according to age, gender, race/ethnicity, income, education and religion.
A total of 1006 completed the questionnaire with an overall response rate of 94%. A majority supported PGD for diseases fatal early in life or those causing lifelong disability (72.9 and 66.7%, respectively); only 48.0% supported PGD for diseases that manifest late in life. Respondents were more supportive of PGD for genetic diseases if they were aware of PGD prior to the survey (OR = 1.64; CI = 1.13-2.39). However, a small proportion were in favor of genetically-based trait selection: 21.1% supported PGD for sex selection, 14.6% for physical traits and 18.9% for personality traits. Compared to women, men were nearly two- to three-fold more supportive of PGD for sex selection (OR = 1.65; CI = 1.20-2.78), physical traits (OR = 2.38; CI = 1.60-3.48) and personality traits (OR = 2.31; CI = .64-3.26). Compared to Caucasians, Asians (OR = 3.87; CI = 1.71-8.78) and African Americans (OR = 1.61; CI = 1.04-2.74) were more supportive of PGD for sex selection.
In a nationally representative sample, a majority supported PGD to identify early onset diseases. We noted significant variation in opinions by sex, race, and education. There was more support among those with prior knowledge of PGD suggesting that education about PGD may foster favorable opinions. This study identifies public knowledge and attitudes that may be used to shape future research hypotheses and clinical policies.
研究美国人群对在各种临床情况下使用植入前基因诊断(PGD)的看法。
根据年龄、性别、种族/民族、收入、教育程度和宗教信仰,对具有全国代表性的样本进行基于网络横断面的人群问卷调查。
共有1006人完成问卷,总体回复率为94%。大多数人支持对早年致命疾病或导致终身残疾的疾病进行PGD(分别为72.9%和66.7%);只有48.0%的人支持对晚年出现的疾病进行PGD。如果受访者在调查前了解PGD,则对遗传性疾病的PGD更支持(OR = 1.64;CI = 1.13 - 2.39)。然而,一小部分人赞成基于基因的性状选择:21.1%的人支持性别选择的PGD,14.6%的人支持身体性状选择,18.9%的人支持性格性状选择。与女性相比,男性对性别选择(OR = 1.65;CI = 1.20 - 2.78)、身体性状(OR = 2.38;CI = 1.60 - 3.48)和性格性状(OR = 2.31;CI = 1.64 - 3.26)的PGD支持率高出近两到三倍。与白种人相比,亚洲人(OR = 3.87;CI = 1.71 - 8.78)和非裔美国人(OR = 1.61;CI = 1.04 - 2.74)对性别选择PGD的支持率更高。
在具有全国代表性的样本中,大多数人支持PGD用于识别早发性疾病。我们注意到性别、种族和教育程度方面的意见存在显著差异。对PGD有先验知识的人支持率更高,这表明关于PGD的教育可能会形成有利的看法。本研究确定了可用于形成未来研究假设和临床政策的公众知识和态度。